RediNews
ETFs Holding ACOR »    ACOR Historical Stock Prices »
ACOR News Video: Wed, Jun 21, 2017, 10:31 AM — Wednesday 6/21 Insider Buying Report: ACOR, SBBX


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Acorda Therapeutics is a biopharmaceutical company focused on developing therapies for neurological disorders. Co.'s marketed therapies include: Ampyra, an extended release tablet formulation of dalfampridine for the treatment of multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. Co. has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease and MS. Co.'s research and development program include SYN120, which is a potential treatment for Parkinson's-related dementia; and BTT1023 (timolumab), a product candidate for the orphan disease Primary Sclerosing Cholangitis. Self directed investors in Acorda Therapeutics Inc will be interested in keeping up with all Acorda Therapeutics Inc news they can find, both ACOR news originating from the company in the form of press releases, as well as seeing how independent media outlets are reporting news on ACOR. At RediNews, we simplify this task by presenting both ACOR news releases originating from Acorda Therapeutics Inc itself, and ACOR news from a variety of media outlets. Visitors can browse this news online and through our ACOR RSS news feed.

ACOR News

ACOR News — Articles, Videos, & Press Releases

Notable Friday Option Activity: UBNT, AAOI, ACOR
Friday, June 8, 2018, 3:26 PM — Stock Options Channel
Acorda Therapeutics Reaches Analyst Target Price
Friday, May 25, 2018, 8:11 AM — ETF Channel
Bullish Two Hundred Day Moving Average Cross - ACOR
Thursday, May 24, 2018, 11:55 AM — Market News Video
Acorda (ACOR) Q1 Earnings Miss Estimates, Sales Down Y/Y
Thursday, May 3, 2018, 9:39 AM — Zacks
Noteworthy Monday Option Activity: HBI, STMP, ACOR
Monday, April 30, 2018, 3:20 PM — Stock Options Channel
New Strong Sell Stocks for April 18th
Wednesday, April 18, 2018, 4:27 AM — Zacks
First Week of ACOR May 18th Options Trading
Tuesday, April 3, 2018, 10:34 AM — Stock Options Channel
Acorda Files Parkinson's Drug Marketing Application in EU
Tuesday, March 27, 2018, 8:00 AM — Zacks
Acorda Therapeutics Reaches Analyst Target Price
Friday, March 2, 2018, 9:24 AM — ETF Channel
First Week of October 19th Options Trading For Acorda Therapeutics (ACOR)
Friday, February 23, 2018, 11:36 AM — Stock Options Channel
Notable Thursday Option Activity: ACOR, VHC, TREE
Thursday, January 18, 2018, 3:16 PM — Stock Options Channel
Notable Monday Option Activity: ACOR, MODN, SCHN
Monday, January 8, 2018, 3:28 PM — Stock Options Channel
Sum Up The Parts: PBE Could Be Worth $55
Friday, January 5, 2018, 9:11 AM — ETF Channel
ACOR Crosses Above Key Moving Average Level
Wednesday, December 13, 2017, 11:41 AM — Market News Video
Interesting ACOR Put Options For November 17th
Thursday, November 16, 2017, 10:33 AM — Stock Options Channel
Implied PBE Analyst Target Price: $57
Thursday, November 16, 2017, 9:27 AM — ETF Channel
Notable Wednesday Option Activity: WMT, ACOR, GNC
Wednesday, November 15, 2017, 3:26 PM — Stock Options Channel
Oversold Conditions For Acorda Therapeutics (ACOR)
Wednesday, November 15, 2017, 11:57 AM — Dividend Channel
First Week of December 15th Options Trading For Acorda Therapeutics (ACOR)
Thursday, November 2, 2017, 10:33 AM — Stock Options Channel
Short Interest In Acorda Therapeutics Drops 12.7%
Wednesday, October 25, 2017, 1:48 PM — Market News Video
Commit To Purchase Acorda Therapeutics At $17, Earn 15.6% Annualized Using Options
Monday, October 23, 2017, 11:46 AM — Stock Options Channel
Acorda Therapeutics Reaches Analyst Target Price
Monday, October 23, 2017, 10:15 AM — ETF Channel
Acorda Therapeutics Stock Sees Short Interest Move 12.6% Higher
Wednesday, September 27, 2017, 1:38 PM — Market News Video
ACOR Crosses Above Average Analyst Target
Wednesday, September 20, 2017, 10:25 AM — ETF Channel
Analysts Expect SLY To Hit $135
Thursday, August 31, 2017, 8:34 AM — ETF Channel
Analysts Forecast 13% Upside For PBE
Monday, July 31, 2017, 10:03 AM — ETF Channel
September 15th Options Now Available For Acorda Therapeutics (ACOR)
Monday, July 24, 2017, 11:39 AM — Stock Options Channel
Short Interest Makes 16% Move For ACOR
Thursday, July 13, 2017, 1:48 PM — Market News Video
PBE's Underlying Holdings Imply 12% Gain Potential
Wednesday, June 28, 2017, 8:44 AM — ETF Channel
Top Buys by Top Brass: CEO Cohen's $339K Bet on ACOR
Wednesday, June 21, 2017, 10:31 AM — Dividend Channel
ACOR is categorized under the Healthcare sector; below are links to news for some other companies in the same sector:

TSRO News
PBYI News
OHRP News
GMED News
NAVB News
ATRS News
DCTH News
FURX News
CMRX News
ALIM News

RediNews invites those seeking web page financial content for any internet portal, especially any vertical portal specializing in the markets where there is a web page for business, web page for markets, web page finance, etc., to integrate our free web site content, our RSS news feeds. These RSS feeds are found throughout our website wherever news and custom stock content is found, by clicking the RSS icon for any news page (which will look like this): . This dynamic financial content is ideal for sites that already feature stock data content such as historical stock price information whether in the form of a historical stock price table or a web page chart image, to supplement the other custom stock market content displayed.

ACOR News | www.RediNews.com | Copyright © 2013 - 2018, All Rights Reserved

Nothing in www.RediNews.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.